The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?
- PMID: 2015114
- DOI: 10.1089/aid.1991.7.3
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?
Abstract
Located close to the crown of the V3 type-specific neutralization loop of the human immunodeficiency virus type 1 (HIV-1) (IIIB) SU glycoprotein gp120, are several potential sites that should be susceptible to proteolytic cleavage by enzymes of trypsinlike or chymotrypsinlike specificity, or by aspartic proteinases. The linkages potentially sensitive to chymotryptic/aspartic proteinase cleavage are retained also within the equivalent domain of HIV-2 (ROD) gp105. We show that thrombin and tryptase cleave HIV-1 gp120 specifically at the tryptic site (GPGR decreases AFVT), and that cathepsin E, an endosomal aspartic proteinase, cleaves at the chymotrypsinlike site (GPGRAF decreases VT). HIV-2 gp105 is also cut by cathepsin E at a site (QIML decreases MSGH) in its V3 loop. Cleavage of HIV-1 gp120 by thrombin is enhanced by sCD4 binding, but is prevented by transient exposure of gp120 to nonionic detergent. Thrombin treatment of HIV-1 gp120 destroys the binding sites for some neutralizing monoclonal antibodies (MAbs) on the V3 loop, but does not affect the affinity of gp120 for sCD4. Conversely, binding of neutralizing MAbs to the HIV-1 V3 loop prior to addition of thrombin or cathepsin E blocks the cleavage reactions, and the binding of some HIV-positive sera to gp120 blocks thrombin cleavage. Analysis of published sequences suggests that all HIV-1, HIV-2, and simian immunovirus (SIV) isolates contain potential proteolytic cleavage sites at similar positions in their V3 loops or equivalent domains. We suggest that cleavage of the V3 loop by a cell surface or endosomal proteinase occurs during the HIV-cell fusion reaction, and that neutralizing antibodies directed against the V3 loop might act by inhibition of this reaction.
Similar articles
-
Effect of mutations in the V3 loop of HIV-1 gp120 on infectivity and susceptibility to proteolytic cleavage.AIDS Res Hum Retroviruses. 1993 Feb;9(2):159-66. doi: 10.1089/aid.1993.9.159. AIDS Res Hum Retroviruses. 1993. PMID: 8457383
-
T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120.Eur J Biochem. 1996 Apr 1;237(1):64-70. doi: 10.1111/j.1432-1033.1996.0064n.x. Eur J Biochem. 1996. PMID: 8620895
-
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.J Clin Invest. 1993 Aug;92(2):840-7. doi: 10.1172/JCI116658. J Clin Invest. 1993. PMID: 8349820 Free PMC article. Clinical Trial.
-
CD4 activation of HIV fusion.Int J Cell Cloning. 1992 Nov;10(6):323-32. doi: 10.1002/stem.5530100603. Int J Cell Cloning. 1992. PMID: 1281202 Review.
-
Antibodies as defensive enzymes.Springer Semin Immunopathol. 2005 Mar;26(4):485-503. doi: 10.1007/s00281-004-0191-1. Epub 2005 Jan 5. Springer Semin Immunopathol. 2005. PMID: 15633014 Review.
Cited by
-
Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry.Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2223-6. doi: 10.1073/pnas.89.6.2223. Proc Natl Acad Sci U S A. 1992. PMID: 1549586 Free PMC article.
-
Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity.J Virol. 1992 Jan;66(1):524-33. doi: 10.1128/JVI.66.1.524-533.1992. J Virol. 1992. PMID: 1727497 Free PMC article.
-
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages.J Virol. 1991 Nov;65(11):5782-9. doi: 10.1128/JVI.65.11.5782-5789.1991. J Virol. 1991. PMID: 1920616 Free PMC article.
-
Virus receptors: implications for pathogenesis and the design of antiviral agents.Clin Microbiol Rev. 1995 Apr;8(2):293-315. doi: 10.1128/CMR.8.2.293. Clin Microbiol Rev. 1995. PMID: 7621403 Free PMC article. Review.
-
Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4.J Virol. 1993 May;67(5):2566-74. doi: 10.1128/JVI.67.5.2566-2574.1993. J Virol. 1993. PMID: 8474162 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources